ICYMI: Last week we announced a collaboration with a leading breast cancer team from Yale Cancer Center for the CATE clinical trial, a novel ctDNA-guided study aimed at improving outcomes in patients with breast cancer. The prospective, multi-center trial, sponsored by the Translational Breast Cancer Research Consortium (TBCRC) and led by Dr. Mariya Rozenblit and Dr. Maryam Lustberg at Yale Cancer Center, will investigate whether earlier, ultrasensitive ctDNA-guided intervention can prevent metastatic relapse and improve outcomes for patients with HR+/HER2- breast cancer. HR+/HER2- breast cancer, which accounts for over 70% of all cases, poses a significant challenge due to the risk of late recurrence. The CATE trial utilizes the NeXT Personal® test to identify the earliest molecular signs of recurrence, ahead of standard imaging. Patients who test positive will be preemptively treated with elacestrant, a next-generation therapy, with the goal of eliminating cancer before it becomes metastatic. Learn more from the press release: https://bit. ly/4grSkT0 See what’s being said in the news about this pivotal trial: https://bit. ly/4pwujym #PrecisionOncology #ctDNA #BreastCancer #ClinicalTrials #PrecisionMedicine #NGS VSports app下载.
最相关的动态
-
V体育安卓版 -
New Horizons in Triple Negative Breast Cancer: Limantrafin–BODIPY Phototherapy In 2025, Dr VSports手机版. shilpendu ghosh and colleagues reported in Small a promising breakthrough for triple negative breast cancer (TNBC). Their study introduced Limantrafin–BODIPY conjugates, next-generation Type-I photosensitizers that efficiently generate superoxide radicals (O₂•⁻) under green light irradiation. This approach achieved an exceptionally high phototherapeutic index (>3700) at low light intensity, with nanoparticle encapsulation enhancing tumor selectivity. Importantly, beyond tumor killing, the therapy reduced stemness-associated genes and downregulated CD44 and ICAM-1, markers linked to metastasis and immune evasion suggesting long-term benefits in reducing recurrence and boosting immunogenic cell death. These findings highlight a novel strategy to overcome PDT limitations and expand the potential of ROS-driven, targeted cancer therapies. We recognize Dr. Shilpendu Ghosh and his research team for their innovative contribution in advancing cancer phototherapy and opening new avenues for TNBC treatment. Read more:https://lnkd. in/d862XtEf #OncologyFrontier #BreastCancer #Phototherapy #CancerResearch #TripleNegativeBreastCancer #InnovationInOncology.
-
-
Up next in our Cancer Research Communications Article Showcase series is a featured selection from Justin Balko, Senior Editor of Immuno-oncology: “Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma” https://brnw. ch/21wWhYC Immunotherapy has revolutionized cancer treatment. However, many patients' tumors still respond suboptimally to immunotherapeutic modalities, necessitating biomarker discovery and rational combination therapies. This study addresses the latter, showing that targeting EGFR and MET with the bispecific antibody amivantamab ameliorates the glycolytic and immunosuppressive response to pembrolizumab in lung and head and neck squamous cell carcinomas. Read the latest articles from this section: https://brnw. ch/21wWhYD V体育ios版.
-
-
Overcoming Resistance to CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer In a recent review published in Cancer Treatment Reviews (2025), Federica Giugliano and colleagues provide an insightful overview of the mechanisms and strategies to overcome resistance to CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer V体育平台登录. While the combination of CDK4/6 inhibitors with endocrine therapy has transformed treatment outcomes, resistance both intrinsic and acquired remains a major clinical challenge. The study highlights key pathways driving resistance and explores innovative therapeutic combinations, including the integration of targeted agents such as PI3K, AKT, and mTOR inhibitors. This review emphasizes the importance of translational research and biomarker-driven approaches to refine treatment sequencing and develop next-generation strategies capable of restoring endocrine sensitivity in resistant HR-positive disease. We thank Federica Giugliano and her co-authors for their significant contribution to advancing our understanding of resistance mechanisms and shaping the future of personalized breast cancer therapy. Read more: https://lnkd. in/dx6dMiqT #BreastCancerResearch #OncologyFrontier #CDK46Inhibitors #EndocrineTherapy #TranslationalResearch #PrecisionOncology #CancerTreatment #HormoneReceptorPositive.
-
-
Pancreatic cancer is among the most treatment-resistant cancers, with only a 13% five-year survival rate V体育官网入口. Researchers at IU Simon Comprehensive Cancer Center and Indiana University School of Medicine have identified a dual-target strategy that weakens the disease's defenses. By blocking two proteins, Ref-1 and PRDX1, researchers saw tumors shrink and fewer cancer cells survive. Notably, this approach disrupted both tumor cells and their surrounding microenvironment, offering a broader path forward in tackling pancreatic cancer and potentially other aggressive cancers. This work underscores the importance of collaborative cancer research and the pursuit of new therapeutic approaches. Learn more: https://ow. ly/aPmq50WYSy9. #ResearchCuresCancer.
-
-
We’re excited to join ESMO - European Society for Medical Oncology 2025, where Principal Investigator, Maximilian Kordes, Assistant Chief Physician in Oncology at the Medical Unit, Center for Clinical Cancer Studies (ME CKC), Karolinska University Hospital, will present a poster featuring the on-going clinical trial in our personalised T-cell therapy programme for colorectal cancer. The poster outlines the first-in-human study of pTTL. Our approach combines precision-selected neoantigens, identified using machine learning, with T cells derived from each patient. 📋 Poster title: First-in-human Phase I/IIa trial of personalised Tumour-Trained Lymphocytes (pTTL) for colorectal cancer 📍 Poster No. 1597eTiP | Investigational Immunotherapy ESMO brings together the global oncology community to explore the latest advances in cancer care, and we’re proud to be part of this year’s dialogue. We are looking forward to connecting with peers and sharing clinical insights. Link to the ESMO programme in the comments. #ESMO2025 #PersonalisedImmunotherapy #CellTherapy #Oncology #pTTL
-
-
October is Breast Cancer and Liver Cancer Awareness Month. Time to raise awareness for the ongoing fight against these diseases and to emphasize the critical role research plays in improving patient outcomes. At Indivumed, we are dedicated to advancing research through our patient-centric R&D approach, discovering novel insights that drive precision oncology forward. This month, we share two significant case reports, demonstrating how data-driven science can identify novel pathways in cancer research: 1️⃣ Breast Cancer Study: Yang, X. et al. examine a primary luminal/ HER2 negative breast cancer patient with mismatch repair deficiency: https://lnkd.in/e_V3YFgp 2️⃣ Liver Cancer Study: Mengting, Z. et al. conduct genomic and transcriptomic profiling of hepatocellular carcinoma revealing a rare molecular subtype: https://lnkd.in/euqQTViw Our commitment to data-driven research continues and we push boundaries with each new insight gained. 🔬 Explore our findings and see how precision makes a difference 👇🏻 #BreastCancerAwareness #LiverCancerAwareness #CancerResearch
-
🧩 Cytomegalovirus (CMV) Status May Predict Response to Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer A new Cancer Letters (2025) study led by Vincent Walter and colleagues explores a novel immunologic biomarker — CMV serostatus — in patients with early triple-negative breast cancer (TNBC) receiving neoadjuvant chemoimmunotherapy. The findings suggest that preexisting CMV immunity could influence treatment response to immune checkpoint inhibition, potentially guiding future patient stratification strategies in TNBC. This discovery opens the door to incorporating viral serology into predictive oncology, advancing precision immunotherapy in aggressive breast cancer subtypes. https://lnkd.in/eFJqrY3K #TripleNegativeBreastCancer #Immunotherapy #OncologyFrontier #MediaMedic #CancerResearch #Biomarkers #CMV #Chemoimmunotherapy
-
-
#OurWorkWednesday We are proud to highlight Cyramza® (ramucirumab), a therapy advancing cancer care through targeted innovation. Cyramza is designed to block VEGFR-2, a key receptor that tumors use to build new blood vessels. By disrupting this pathway it helps slow disease progression and offers new hope for patients facing some of the most challenging cancers. Approved across multiple indications: - Advanced gastric and gastroesophageal junction cancers. - Metastatic non-small cell lung cancer. - Metastatic colorectal cancer. - Hepatocellular carcinoma with high AFP levels. OptiBrand celebrates treatments like Cyramza, because each advance in science brings us closer to more effective, life-extending options for patients worldwide. Learn more: https://cyramza.lilly.com/ #OptiBrandRx #OurWorkWednesday #AllInAlways #OBRxPartners #Cyramza #Oncology #CancerCare
-
-
Ribociclib–Letrozole Combination as an Alternative to Neoadjuvant Chemotherapy in Luminal Breast Cancer (BOOG 2017-01) A phase II clinical trial published in Clinical Cancer Research (2025) evaluated whether ribociclib plus letrozole (RL) could serve as a less toxic alternative to standard neoadjuvant chemotherapy (CT) in postmenopausal women with hormone receptor-positive, HER2-negative early-stage luminal breast cancer. The NEOLBC trial found that the complete cell-cycle arrest rate (Ki67 <1%) and pathologic response were comparable between RL and CT (35.3% vs 31.3%), while toxicity was notably lower in the RL group. Although the primary endpoint was not met, these findings suggest that CDK4/6 inhibition combined with endocrine therapy could represent a well-tolerated alternative to chemotherapy in selected patients. 📖 Read more: https://lnkd.in/dz8wX3N6 Thanks to the study authors for their contribution to advancing tailored treatment approaches in luminal breast cancer. #OncologyFrontier #BreastCancer #Ribociclib #EndocrineTherapy #CDK46Inhibitors #ClinicalResearch #BreastCancerTreatment
-
-
PhD Immunotherapy Expert | R&D | TCEs | bi-specific, tri-specific abs | CAR-T, TCR-T & MSCs | Assay Development | Analytical Development | Process Development | Immuno-oncology| Extracellular vesicles
A recent study from MD Anderson Cancer Center illustrates how oncogene targeting and T-cell based immunotherapy can converge to tackle pancreatic cancer, a tumor type typically poorly accessible to immune cells. The authors show that exosomes delivering siRNA against mutant KRAS silence oncogenic signaling and reprogram the tumor microenvironment. Remarkably, this also restores CD8 T-cell infiltration and synergizes with CTLA-4 blockade. The next generation of therapies may not choose between oncogene targeting and immune modulation but use both in a powerful combination converting cold, immune excluded tumors into immune responsive ones.
